Linked Life Data

12121503

Source:http://linkedlifedata.com/resource/pubmed/id/12121503

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2002-7-17
pubmed:abstractText
Genetic polymorphism of cytochrome P450 (CYP) 2C19 influences the efficacy of Helicobacter pylori eradication therapy with a proton pump inhibitor (PPI) and amoxicillin. However, in triple therapy (PPI plus amoxicillin and clarithromycin), little is known about the impact of CYP2C19 polymorphism, or the use of rabeprazole, which is not well metabolized by CYP2C19. The efficacy of three PPI (omeprazole, lansoprazole, and rabeprazole) in a 1-week triple regimen were compared in relation to CYP2C19 polymorphism.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/2-Pyridinylmethylsulfinylbenzimidazo..., http://linkedlifedata.com/resource/pubmed/chemical/Amoxicillin, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Ulcer Agents, http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases, http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles, http://linkedlifedata.com/resource/pubmed/chemical/CYP2C19 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Clarithromycin, http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System, http://linkedlifedata.com/resource/pubmed/chemical/DNA, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases, http://linkedlifedata.com/resource/pubmed/chemical/Omeprazole, http://linkedlifedata.com/resource/pubmed/chemical/Proton Pumps, http://linkedlifedata.com/resource/pubmed/chemical/lansoprazole, http://linkedlifedata.com/resource/pubmed/chemical/rabeprazole
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0815-9319
pubmed:author
pubmed:copyrightInfo
Copyright 2002 Blackwell Publishing Asia Pty Ltd
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
748-53
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12121503-2-Pyridinylmethylsulfinylbenzimidazoles, pubmed-meshheading:12121503-Adult, pubmed-meshheading:12121503-Aged, pubmed-meshheading:12121503-Aged, 80 and over, pubmed-meshheading:12121503-Amoxicillin, pubmed-meshheading:12121503-Anti-Ulcer Agents, pubmed-meshheading:12121503-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:12121503-Benzimidazoles, pubmed-meshheading:12121503-Clarithromycin, pubmed-meshheading:12121503-Cytochrome P-450 Enzyme System, pubmed-meshheading:12121503-DNA, pubmed-meshheading:12121503-Drug Therapy, Combination, pubmed-meshheading:12121503-Enzyme Inhibitors, pubmed-meshheading:12121503-Female, pubmed-meshheading:12121503-Genotype, pubmed-meshheading:12121503-Helicobacter Infections, pubmed-meshheading:12121503-Helicobacter pylori, pubmed-meshheading:12121503-Humans, pubmed-meshheading:12121503-Male, pubmed-meshheading:12121503-Middle Aged, pubmed-meshheading:12121503-Mixed Function Oxygenases, pubmed-meshheading:12121503-Omeprazole, pubmed-meshheading:12121503-Peptic Ulcer, pubmed-meshheading:12121503-Polymerase Chain Reaction, pubmed-meshheading:12121503-Polymorphism, Restriction Fragment Length, pubmed-meshheading:12121503-Prospective Studies, pubmed-meshheading:12121503-Proton Pumps, pubmed-meshheading:12121503-Treatment Outcome
pubmed:year
2002
pubmed:articleTitle
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
pubmed:affiliation
Department of Internal Medicine, Kagawa Prefectural Central Hospital, Japan.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial